AGÕæÈ˹ٷ½

STOCK TITAN

TransMedics to Present at the Canaccord Genuity 45th Annual Growth Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

TransMedics (NASDAQ: TMDX), a medical technology company specializing in organ transplant therapy solutions, announced its participation in the Canaccord Genuity 45th Annual Growth Conference. The company's management team will deliver a presentation on Tuesday, August 12, 2025, at 11:30 a.m. ET at the InterContinental Boston Hotel.

Investors can access both the live and archived webcast of the fireside chat, along with the company's standard investor presentation, through the "Investors" section of TransMedics' website at investors.transmedics.com.

TransMedics (NASDAQ: TMDX), un'azienda di tecnologia medica specializzata in soluzioni per la terapia dei trapianti d'organo, ha annunciato la sua partecipazione alla 45ª Conferenza Annuale sulla Crescita di Canaccord Genuity. Il team di gestione della società terrà una presentazione martedì 12 agosto 2025, alle 11:30 ET presso l'InterContinental Boston Hotel.

Gli investitori potranno accedere sia alla diretta che alla registrazione web del dialogo informale, insieme alla presentazione standard per gli investitori, tramite la sezione "Investitori" del sito web di TransMedics all'indirizzo investors.transmedics.com.

TransMedics (NASDAQ: TMDX), una empresa de tecnología médica especializada en soluciones para terapia de trasplantes de órganos, anunció su participación en la 45ª Conferencia Anual de Crecimiento de Canaccord Genuity. El equipo directivo de la empresa realizará una presentación el martes 12 de agosto de 2025, a las 11:30 a.m. ET en el Hotel InterContinental Boston.

Los inversores pueden acceder tanto a la transmisión en vivo como a la grabación del diálogo informal, junto con la presentación estándar para inversores, a través de la sección "Inversores" en el sitio web de TransMedics en investors.transmedics.com.

TransMedics (NASDAQ: TMDX)ëŠ� 장기 ì´ì‹ 치료 ì†”ë£¨ì…˜ì„ ì „ë¬¸ìœ¼ë¡œ 하는 ì˜ë£Œ 기술 회사ë¡�, Canaccord Genuity ì �45íš� ì—°ë¡€ 성장 컨í¼ëŸ°ìФì—� 참여한다ê³� 발표했습니다. 회사 ê²½ì˜ì§„ì€ 2025ë…� 8ì›� 12ì� 화요ì� 오전 11ì‹� 30ë¶�(ë™ë¶€ì‹œê°„)ì—� 보스í„� ì¸í„°ì»¨í‹°ë„¨íƒˆ 호텔ì—서 발표ë¥� ì§„í–‰í•� 예정입니ë‹�.

투ìžìžë“¤ì€ TransMedics 웹사ì´íЏì� "투ìžìž�" 섹션 investors.transmedics.comì� 통해 ë¼ì´ë¸� ë°� 녹화ë� í™”ìƒ í† ë¡ ê³� 회사ì� 표준 투ìžìž� 프레젠테ì´ì…˜ì—� ì ‘ì†í•� ìˆ� 있습니다.

TransMedics (NASDAQ : TMDX), une entreprise de technologie médicale spécialisée dans les solutions de thérapie pour la transplantation d'organes, a annoncé sa participation à la 45e conférence annuelle sur la croissance de Canaccord Genuity. L'équipe de direction de l'entreprise présentera une intervention le mardi 12 août 2025 à 11h30 (heure de l'Est) à l'hôtel InterContinental de Boston.

Les investisseurs peuvent accéder à la fois au webcast en direct et à l'archive de la discussion informelle, ainsi qu'à la présentation standard pour les investisseurs, via la section « Investisseurs » du site web de TransMedics à l'adresse investors.transmedics.com.

TransMedics (NASDAQ: TMDX), ein Medizintechnikunternehmen, das sich auf Organtransplantationstherapielösungen spezialisiert hat, gab seine Teilnahme an der 45. jährlichen Wachstumskonferenz von Canaccord Genuity bekannt. Das Managementteam des Unternehmens wird am Dienstag, den 12. August 2025, um 11:30 Uhr ET im InterContinental Boston Hotel eine Präsentation halten.

Investoren können sowohl den Live-Stream als auch die Aufzeichnung des Gesprächs sowie die reguläre Investorenpräsentation über den Bereich "Investoren" auf der Website von TransMedics unter investors.transmedics.com abrufen.

Positive
  • None.
Negative
  • None.

ANDOVER, Mass., July 29, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will present at the upcoming Canaccord Genuity 45th Annual Growth Conference at the InterContinental Boston Hotel. Management is scheduled to present on Tuesday, August 12, 2025, at 11:30 a.m. Eastern Standard Time.

Event: Canaccord Genuity 45th Annual Growth Conference
Date: Tuesday, August 12, 2025
Time: 11:30 a.m. ET

A live and archived webcast of the fireside chat will be available on the "Investors" section of the TransMedics website at . The Company's standard investor presentation is also available through this link.

About TransMedics Group, Inc.

TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.

Investor Contact:
Brian Johnston
Laine Morgan
332-895-3222
[email protected]

Cision View original content to download multimedia:

SOURCE TransMedics Group, Inc.

FAQ

When is TransMedics (TMDX) presenting at the Canaccord Genuity Conference 2025?

TransMedics will present on Tuesday, August 12, 2025, at 11:30 a.m. Eastern Standard Time at the InterContinental Boston Hotel.

How can investors watch TransMedics' (TMDX) Canaccord conference presentation?

Investors can access the live and archived webcast of the fireside chat through the 'Investors' section of TransMedics' website at investors.transmedics.com.

What does TransMedics (TMDX) specialize in?

TransMedics is a medical technology company that develops organ transplant therapy solutions for patients with end-stage lung, heart, and liver failure.

Where is the Canaccord Genuity Growth Conference 2025 being held?

The conference is being held at the InterContinental Boston Hotel in Boston.
Transmedics Group

NASDAQ:TMDX

TMDX Rankings

TMDX Latest News

TMDX Latest SEC Filings

TMDX Stock Data

3.64B
32.81M
3.5%
115.88%
27.72%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
United States
ANDOVER